TSBX Key Statistics, Chart & Performance
The current stock price of TSBX is 0.355 USD. In the past month the price decreased by -3.56%. In the past year, price decreased by -84.63%.
TSBX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About TSBX
Company Profile
Turnstone Biologics Corp. operates as a clinical stage biotechnology company. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2023-07-21. The firm is focused on developing new medicines to treat and cure patients with solid tumors. The company is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. The company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. The company is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.
Company Info
TURNSTONE BIOLOGICS CORP
9310 Athena Circle, Suite 300
La Jolla CALIFORNIA US
Employees: 82
Phone: 13478975988
TURNSTONE BIOLOGICS CORP / TSBX FAQ
What does TURNSTONE BIOLOGICS CORP do?
Turnstone Biologics Corp. operates as a clinical stage biotechnology company. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2023-07-21. The firm is focused on developing new medicines to treat and cure patients with solid tumors. The company is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. The company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. The company is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.
What is the current price of TSBX stock?
The current stock price of TSBX is 0.355 USD. The price increased by 1.43% in the last trading session.
Does TSBX stock pay dividends?
TSBX does not pay a dividend.
What is the ChartMill technical and fundamental rating of TSBX stock?
TSBX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for TURNSTONE BIOLOGICS CORP?
TURNSTONE BIOLOGICS CORP (TSBX) currently has 82 employees.
TSBX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TSBX. When comparing the yearly performance of all stocks, TSBX is a bad performer in the overall market: 95.57% of all stocks are doing better.
TSBX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TSBX. TSBX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TSBX Financial Highlights
Over the last trailing twelve months TSBX reported a non-GAAP Earnings per Share(EPS) of -2.05. The EPS increased by 41.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -228.2% | ||
| ROE | -315.29% | ||
| Debt/Equity | 0 |
TSBX Forecast & Estimates
6 analysts have analysed TSBX and the average price target is 1.02 USD. This implies a price increase of 187.32% is expected in the next year compared to the current price of 0.355.